Clinical Trials Logo

Clinical Trial Summary

To date, the investigators lack characterization of, the burden of, and the systemic progression of disease in ENPP1 deficiency and ABCC6 deficiency from a patient and/or parent perspective. This study aims to document this characterization, progression as well as the burden of disease. Link to the study registration- https://www.engagehealth.com/survey/TakeSurvey.aspx?SurveyID=8252n62


Clinical Trial Description

This will be a comprehensive, cross-sectional study conducted in approximately 60 individuals (or representative parents of patients) affected by ENPP1 deficiency and the acute form of ABCC6 deficiency. All study participants will complete the RSVP, PRO tools and upload a proof of disease form, followed by an interview conducted by a trained interviewer. It is estimated that each respondent will need up to 60 minutes for the entire process; 20 minutes to complete the RSVP, PRO tools and to upload proof of diagnosis of ENPP1 deficiency or the acute form of ABBC6 deficiency, and approximately 40 minutes to complete the interview and address any follow-up questions if needed. ;


Study Design


Related Conditions & MeSH terms

  • Autosomal Recessive Hypophosphatemic Rickets Type 2
  • Familial Hypophosphatemic Rickets
  • Generalized Arterial Calcification in Infancy
  • Rickets

NCT number NCT04372446
Study type Observational
Source Inozyme Pharma
Contact
Status Completed
Phase
Start date May 6, 2020
Completion date September 30, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT03758534 - Natural History of GACI With or Without ARHR2 or PXE